Liraglutide as First-Line Therapy for Type 2 Diabetics With Post–COVID-19 Fatigue Syndrome and Executive Function Deficits : American Journal of Therapeutics

Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
Editorial

Liraglutide as First-Line Therapy for Type 2 Diabetics With Post–COVID-19 Fatigue Syndrome and Executive Function Deficits

Manu, Peter MD

Author Information
doi: 10.1097/MJT.0000000000001475
  • Buy
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.